Evidence map›Paper›PMID 12368214›Full record

ArticleThe American journal of pathology2002

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.

Evan Romas, Natalie A Sims, Daphne K Hards, Mandy Lindsay, Julian W M Quinn, Peter F J Ryan, Colin R Dunstan, T John Martin, Matthew T Gillespie

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 365 citations in OpenAlex.

  1. Trial
  2. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012
    Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Targeting Some Key Metalloproteinases by Nano-Naringenin andPharmaceuticals (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Microorganisms · 2021
    Article
  12. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Evan RomasUniversity of Melbourne, the Department of Medicine, St. Vincent's Hospital, Fitzroy, Victoria, Australia. romase@svhm.org.au
Natalie A Sims
Daphne K Hards
Mandy Lindsay
Julian W M Quinn
Peter F J Ryan
Colin R Dunstan
T John Martin
Matthew T Gillespie
St Vincents Institute of Medical Research · AUMonash University · AUSt Vincent's Hospital · AUAmgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis is characterized by progressive synovial inflammation and joint destruction. While matrix metalloproteinases (MMPs) are implicated in the erosion of unmineralized cartilage, bone destruction involves osteoclasts, the specialized cells that resorb calcified bone matrix. RANK ligand (RANKL) expressed by stromal cells and T cells, and its cognate receptor, RANK, were identified as a critical ligand-receptor pair for osteoclast differentiation and survival. A decoy receptor for RANKL, osteoprotegerin, (OPG) impinges on this system and regulates osteoclast numbers and activity. RANKL is also expressed in collagen-induced arthritis (CIA) in which focal collections of osteoclasts are prominent at sites of bone destruction. To determine the role of RANK signaling events in the effector phase of CIA, we investigated effects of Fc-osteoprotegerin fusion protein (Fc-OPG) in CIA. After induction of CIA in Dark Agouti rats, test animals were treated with or without Fc-OPG (3 mg/kg/day) subcutaneously for 5 days, beginning at the onset of disease. Paraffin-embedded joints were then analyzed histologically and the adjacent bone assessed by histomorphometry. Osteoclasts were identified using TRAP staining and expression of the mRNA for OPG and RANKL was identified by in situ hybridization. The results indicated that short-term Fc-OPG effectively prevented joint destruction, even though it had no impact on the inflammatory aspects of CIA. In arthritic joints, Fc-OPG depleted osteoclast numbers by over 75% and diminished bone erosion scores by over 60%. Although cartilage loss was also reduced by Fc-OPG, the effects on cartilage were less striking than those on bone. In arthritic joints OPG mRNA was highly expressed and co-localized with RANK ligand, and treatment with Fc-OPG did not affect the expression of endogenous RANKL or OPG mRNA. These data demonstrate that short term Fc-OPG treatment has powerful anti-erosive effects, principally on bone, even though synovitis is not affected. These findings indicate the potential utility of disrupting RANK signaling to preserve skeletal integrity in inflammatory arthritis.

Indexed as

AnimalsArthritis, ExperimentalBone DiseasesCarrier ProteinsCollagenGlycoproteinsMembrane GlycoproteinsOsteoclastsOsteoprotegerinRANK LigandRatsReceptors, Cytoplasmic and NuclearReceptors, Tumor Necrosis FactorTime FactorsTranscription, GeneticTumor Necrosis Factor-alphaCarrier ProteinsCollagenGlycoproteinsMembrane GlycoproteinsOsteoprotegerinRANK LigandReceptors, Cytoplasmic and NuclearReceptors, Tumor Necrosis FactorTnfrsf11b protein, ratTumor Necrosis Factor-alpha

Identifiers

PMID12368214
PMCPMC1867274
OpenAlexW2032384549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.